Novartis AG Income Statement 2025-2011 | NVS

Brief overview of financial performance at Novartis AG

The figures are compared over a five-year interval. According to figures from Novartis AG, revenue changed from 50.4 billion dollars to 49.9 billion dollars over five years. Across the full period, sales moved by −1%; the average annual rate was −0.2%. The scale of the core business was largely unchanged.

Gross profit changed from $33 billion to $34.8 billion (+5.4%). The gross margin was 65.5% at the start and 69.7% at the end. The business retained more gross profit from each unit of revenue.

EBITDA was 14.4 billion dollars at the beginning and 10.2 billion dollars at the end of the period (−29.7%). Changes in revenue did not translate into comparable EBITDA performance. EBITDA margin was 28.7% at the start and 20.3% at the end. The business retained less EBITDA from each unit of revenue.

Net profit was 17.8 billion dollars at the start and 8.1 billion dollars at the end. The final result developed less favorably than the core business.

Over the period, capitalization shifted from 168 billion dollars to 198 billion dollars (+18.2%). Investor expectations increased faster than reported performance.

Financial takeaway

The financial trajectory is weak and requires a cautious interpretation. Key strengths include better sales economics. The most visible risks are a softer top-line trend, weaker operating efficiency and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.